Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective APOE2 protein in the CNS and decreased core Alzheimer’s disease-related...
-
- Phase 1/2 clinical trial expected to initiate in mid-2022 - - LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate...
-
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...
-
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...
-
Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical...
-
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced...
-
LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic...
-
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
-
Data evaluating intravenous delivery of the AAVrh.10 viral vector show effectiveness in providing high levels of gene transfer to the heart for the potential treatment of rare cardiac diseases ...
-
LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease Initial Phase 1 clinical data expected in 2H 2021 NEW YORK, April 20,...